Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

被引：5
|
作者：
Cardillo, Thomas M.
Mostafa, Ali A.
Rossi, Diane L.
Liu, Donglin
Chang, Chien-Hsing
Sharkey, Robert M.
Goldenberg, David M.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3193
引用
收藏
页数：2
相关论文
共 20 条
  • [11] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Messersmith, Wells A.
    Mayer, Ingrid A.
    Isakoff, Steven J.
    Abramson, Vandana Gupta
    Berlin, Jordan
    Starodub, Alexander
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Moroose, Rebecca L.
    Shah, Nikita C.
    Juric, Dejan
    Shapiro, Geoffrey
    Guarino, Michael J.
    Ocean, Allyson J.
    Wilhelm, Francois
    Sharkey, Robert M.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [12] Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
    Llop-Guevara, A.
    Loibl, S.
    Villacampa, G.
    Vladimirova, V.
    Schneeweiss, A.
    Karn, T.
    Zahm, D. -m.
    Herencia-Ropero, A.
    Jank, P.
    van Mackelenbergh, M.
    Fasching, P. A.
    Marme, F.
    Stickeler, E.
    Schem, C.
    Dienstmann, R.
    Florian, S.
    Nekljudova, V.
    Balmana, J.
    Hahnen, E.
    Denkert, C.
    Serra, V.
    ANNALS OF ONCOLOGY, 2021, 32 (12) : 1590 - 1596
  • [13] Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
    Llop-Guevara, A.
    Vladimirova, V.
    Schneeweiss, A.
    Villacampa, G.
    Karn, T.
    Zahm, D-M.
    Herencia-Ropero, A.
    Jank, P.
    van Mackelenbergh, M.
    Fasching, P. A.
    Marme, F.
    Stickeler, E.
    Schem, C.
    Dienstmann, R.
    Florian, S.
    Nekljudova, V.
    Balmana, J.
    Denkert, C.
    Loibl, S.
    Serra, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S22 - S22
  • [14] IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results
    Goldenberg, David M.
    Vahdat, Linda T.
    Starodub, Alexander N.
    Bardia, Aditya
    Chuang, Ellen
    Moroose, Rebecca L.
    Diamond, Jennifer R.
    Sharkey, Robert M.
    Maliakal, Pius P.
    Hamburger, Steven A.
    Ocean, Allyson J.
    CANCER RESEARCH, 2015, 75
  • [15] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Tolaney, Sara M.
    Santin, Alessandro D.
    Abramson, Vandana
    Shah, Nikita C.
    Govindan, Serengulam V.
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Mayer, Ingrid A.
    CANCER RESEARCH, 2018, 78 (04)
  • [16] Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies
    Hong, Lisa
    Braden, Dennis C.
    Zhao, Yaoning
    Skoko, John J.
    Chang, Fei
    Woodcock, Steven R.
    Uvalle, Crystall
    Casey, Allison
    Wood, Katherine
    Salvatore, Sonia R.
    Asan, Alparslan
    Harkness, Trey
    Fagunloye, Adeola
    Razzaghi, Mortezaali
    Straub, Adam
    Spies, Maria
    Brown, Daniel D.
    Lee, Adrian, V
    Schopfer, Francisco
    Freeman, Bruce A.
    Neumann, Carola A.
    REDOX BIOLOGY, 2023, 66
  • [17] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
    Bardia, Aditya
    Starodub, Alexander
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Chuang, Ellen
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Maliakal, Pius
    Wegener, William A.
    Hamburger, Steven A.
    Ocean, Allyson J.
    Goldenberg, David M.
    Vahdat, Linda T.
    CANCER RESEARCH, 2015, 75
  • [18] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
    Cardillo, Thomas M.
    Sharkey, Robert M.
    Rossi, Diane L.
    Arrojo, Roberto
    Mostafa, Ali A.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
  • [19] VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes
    Tutt, Andrew
    Stephens, Christine
    Frewer, Paul
    Pierce, Andrew
    Rhee, Joon
    So, Karen
    Ottesen, Lone
    Dean, Emma
    Hollingsworth, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [20] Single Nucleotide Polymorphisms (SNPs) of RAD51-G172T and XRCC2-41657C/T Homologous Recombination Repair Genes and the Risk of Triple- Negative Breast Cancer in Polish Women
    Michalska, Magdalena M.
    Samulak, Dariusz
    Romanowicz, Hanna
    Smolarz, Beata
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) : 935 - 940
12